LAVA Reconciled Depreciation from 2010 to 2024

LVTX Stock  USD 1.60  0.05  3.23%   
LAVA Therapeutics Reconciled Depreciation yearly trend continues to be fairly stable with very little volatility. Reconciled Depreciation will likely drop to about 715.4 K in 2024. During the period from 2010 to 2024, LAVA Therapeutics Reconciled Depreciation regression line of annual values had r-squared of  0.55 and arithmetic mean of  404,296. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2018-12-31
Previous Quarter
247 K
Current Value
228 K
Quarterly Volatility
118.7 K
 
Covid
Check LAVA Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LAVA Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 158.4 K, Net Interest Income of 3.1 M or Depreciation And Amortization of 1.3 M, as well as many indicators such as Price To Sales Ratio of 5.93, Dividend Yield of 0.0 or PTB Ratio of 0.78. LAVA financial statements analysis is a perfect complement when working with LAVA Therapeutics Valuation or Volatility modules.
  
Check out the analysis of LAVA Therapeutics Correlation against competitors.

Latest LAVA Therapeutics' Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of LAVA Therapeutics NV over the last few years. It is LAVA Therapeutics' Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LAVA Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

LAVA Reconciled Depreciation Regression Statistics

Arithmetic Mean404,296
Geometric Mean335,129
Coefficient Of Variation75.92
Mean Deviation228,701
Median233,000
Standard Deviation306,958
Sample Variance94.2B
Range1M
R-Value0.74
Mean Square Error46.1B
R-Squared0.55
Significance0
Slope50,693
Total Sum of Squares1.3T

LAVA Reconciled Depreciation History

2024715.4 K
20231.3 M
2022781 K
2021558 K
2020402 K

About LAVA Therapeutics Financial Statements

LAVA Therapeutics investors use historical fundamental indicators, such as LAVA Therapeutics' Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LAVA Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation1.3 M715.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LAVA Stock Analysis

When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.